CC vs. BCPC, HUN, LTHM, ASH, UNVR, NGVT, IOSP, OLN, PRM, and FMC
Should you be buying Chemours stock or one of its competitors? The main competitors of Chemours include Balchem (BCPC), Huntsman (HUN), Livent (LTHM), Ashland (ASH), Univar Solutions (UNVR), Ingevity (NGVT), Innospec (IOSP), Olin (OLN), Perimeter Solutions (PRM), and FMC (FMC). These companies are all part of the "chemicals & allied products" industry.
Chemours vs.
Chemours (NYSE:CC) and Balchem (NASDAQ:BCPC) are both mid-cap basic materials companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
In the previous week, Balchem had 2 more articles in the media than Chemours. MarketBeat recorded 6 mentions for Balchem and 4 mentions for Chemours. Balchem's average media sentiment score of 0.61 beat Chemours' score of 0.26 indicating that Balchem is being referred to more favorably in the news media.
71.9% of Chemours shares are held by institutional investors. Comparatively, 89.3% of Balchem shares are held by institutional investors. 1.6% of Chemours shares are held by insiders. Comparatively, 1.6% of Balchem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Chemours received 240 more outperform votes than Balchem when rated by MarketBeat users. However, 67.25% of users gave Balchem an outperform vote while only 62.39% of users gave Chemours an outperform vote.
Chemours has higher revenue and earnings than Balchem. Chemours is trading at a lower price-to-earnings ratio than Balchem, indicating that it is currently the more affordable of the two stocks.
Chemours currently has a consensus target price of $36.33, suggesting a potential upside of 22.62%. Balchem has a consensus target price of $140.00, suggesting a potential upside of 12.09%. Given Chemours' higher possible upside, equities analysts clearly believe Chemours is more favorable than Balchem.
Chemours has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Comparatively, Balchem has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Balchem has a net margin of 11.18% compared to Chemours' net margin of 8.51%. Chemours' return on equity of 61.75% beat Balchem's return on equity.
Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 3.4%. Balchem pays an annual dividend of $0.71 per share and has a dividend yield of 0.6%. Chemours pays out 28.0% of its earnings in the form of a dividend. Balchem pays out 21.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Summary
Chemours beats Balchem on 11 of the 20 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemours Competitors List
